6.76
+0.28(+4.32%)
Currency In USD
| Previous Close | 6.48 |
| Open | 6.47 |
| Day High | 6.83 |
| Day Low | 6.3 |
| 52-Week High | 7.19 |
| 52-Week Low | 1.78 |
| Volume | 1.47M |
| Average Volume | 1.74M |
| Market Cap | 1.17B |
| PE | -3.54 |
| EPS | -1.91 |
| Moving Average 50 Days | 4.79 |
| Moving Average 200 Days | 3.78 |
| Change | 0.28 |
If you invested $1000 in Relay Therapeutics, Inc. (RLAY) since IPO date, it would be worth $192.87 as of October 24, 2025 at a share price of $6.76. Whereas If you bought $1000 worth of Relay Therapeutics, Inc. (RLAY) shares 3 years ago, it would be worth $334.65 as of October 24, 2025 at a share price of $6.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
GlobeNewswire Inc.
Aug 28, 2025 8:05 PM GMT
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic dise
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
GlobeNewswire Inc.
Jul 31, 2025 8:05 PM GMT
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies,
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
GlobeNewswire Inc.
Jun 11, 2025 8:05 PM GMT
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies,